Rezpegaldesleukin Delivers Year-Long Alopecia Areata Data

Nektar Therapeutics released 52-week durability data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin this morning, April 20, 2026 — the first full-year readout for a regulatory T cell (Treg) proliferator in severe alopecia areata. The data, presented via investor webcast and morning press release, extend the earlier 36-week induction results, which showed a 28-30% mean reduction in the Severity of Alopecia Tool (SALT) score across drug arms versus a 5-11% reduction with placebo, achieving statistical significance after excluding four patients who did not meet study eligibility criteria at baseline.

The Immune Mechanism Behind Alopecia Areata — and Why JAK Inhibitors Only Go Partway

Alopecia areata is not a cosmetic condition. It is an organ-specific autoimmune disease in which cytotoxic CD8+ T cells attack hair follicles, collapsing the immune privilege that normally shields them from immune surveillance. This distinction matters because it explains why treatments that address symptoms without correcting the underlying immune error tend to require indefinite use — and carry the risks that come with sustained immune suppression.

The current standard of care relies on JAK inhibitors — baricitinib (FDA-approved 2022) and ritlecitinib (2023) — which suppress downstream cytokine signaling to interrupt the CD8+ attack. They work, but they do not restore immune regulation. They override it. The safety implications follow: JAK inhibitor labeling carries black box warnings for serious infections, major adverse cardiovascular events, thrombosis, and malignancies, requiring routine laboratory monitoring. For patients weighing long-term treatment options for hair loss, the benefit-risk calculation is real.

Rezpegaldesleukin takes a mechanistically different route. The drug is a pegylated IL-2 conjugate engineered to selectively engage the IL-2 receptor complex expressed at high levels on regulatory T cells. By stimulating Treg proliferation, it aims to re-establish the immune checkpoint that breaks down in alopecia areata — restoring balance rather than enforcing suppression. The same Treg mechanism drives Nektar's parallel program in atopic dermatitis, where Treg dysregulation also contributes to persistent disease.

How Does Rezpegaldesleukin Compare to Approved Alopecia Areata Treatments?

The 36-week REZOLVE-AA data showed 29-30% of patients in the high-dose arms achieving an absolute SALT score of 30 or below — representing at least 70% scalp coverage — compared to 8.4% in the placebo arm, with hair regrowth extending to eyebrows and eyelashes in approximately 50% of the high-dose group.

Investigators noted no plateau in the response curve at week 36. In a post-AAD interview published by Healio on March 28, 2026, Dr. David Rosmarin described the data as evidence of continued improvement trajectories — a critical consideration in a condition where hair regrowth is slow and nonlinear. Today's 52-week extension data directly addresses whether that trajectory holds.

The safety profile reported through 52 weeks of treatment showed no increased risk for major adverse cardiovascular events, thrombosis, infection, malignancy, or oral herpes versus placebo. Injection site reactions, the primary adverse event, were 87% mild with no discontinuations. That profile stands apart from the JAK inhibitor class, and for patients with concurrent inflammatory skin conditions where JAK inhibitor safety monitoring adds complexity, a cleaner immunological approach carries practical weight.

The National Alopecia Areata Foundation's summary of the Phase 2b data described the results as "proof of concept that REZPEG can stimulate meaningful hair regrowth in people with severe to very severe alopecia areata" — a population for whom full-head coverage remains elusive even with approved therapies.

When Could Rezpegaldesleukin Reach Patients?

Nektar plans to advance rezpegaldesleukin into Phase 3 for alopecia areata in 2026, supported by an FDA Fast Track designation granted in July 2025. Phase 3 timelines for biologic dermatology therapies typically run two to three years, placing a potential FDA filing in the 2028-2029 window at the earliest.

Today's 52-week data will directly inform Phase 3 dose selection, treatment duration criteria, and endpoint definitions. For patients with severe disease who are not candidates for JAK inhibitors, or who have not achieved adequate response on approved therapies, a Treg-restorative option represents a path grounded in a different mechanism entirely. Whether that translates into a durable remission, rather than suppression-dependent maintenance, is the core scientific question — and the one today's data begins to answer.